← 治験一覧に戻る
活動性強直性脊椎炎を有する日本人患者におけるセクキヌマブの有効性および安全性に関する研究
基本情報
- NCT ID
- NCT02750592
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 30
- 治験依頼者名
- Novartis
概要
The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal anti-inflammatory drugs (NSAIDs) and/or anti-tumor necrosis factor (TNF) α therapy. Efficacy and safety data were used to support the registration of secukinumab in Japan for the treatment of active AS.
対象疾患
Ankylosing Spondylitis
介入
Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.(DRUG)
依頼者（Sponsor）
ノバルティスファーマ株式会社(INDUSTRY)